Parmax Pharma Ltd Quarterly Result
Parmax Pharma Ltd
NSE: PARMAXPHARMA
Net Profit - Last Quarter
Parmax Pharma Ltd Quarterly Results Key Highlights
- The revenue of Parmax Pharma Ltd for the Jun '26 is ₹ 10.3 crore as compare to the Mar '26 revenue of ₹ 3.34 crore.
- This represent the growth of 208.38% The ebitda of Parmax Pharma Ltd for the Jun '26 is ₹ 2.91 crore as compare to the Mar '26 ebitda of ₹ -1.52 crore.
- This represent the decline of -291% The net profit of Parmax Pharma Ltd for the Jun '26 is ₹ 2.2 crore as compare to the Mar '26 net profit of ₹ -0.58 crore.
- This represent the decline of -479%.
Parmax Pharma Ltd Quarterly Results Analysis
Market Price of Parmax Pharma Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
| Date |  Price (₹) |
|---|---|
| 15 Sep 2026 | 135.05 |
| 07 Sep 2026 | 133.75 |
| 31 Aug 2026 | 132.45 |
| 24 Aug 2026 | 131.15 |
| 21 Aug 2026 | 129.9 |
| 20 Aug 2026 | 127.4 |
| 19 Aug 2026 | 124.95 |
| 18 Aug 2026 | 122.5 |
| 17 Aug 2026 | 120.1 |
| 14 Aug 2026 | 117.75 |
Historical Revenue of Parmax Pharma Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Historical Revenue of Parmax Pharma Ltd
Historical EBITDA of Parmax Pharma Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of Parmax Pharma Ltd
Historical Net Profit of Parmax Pharma Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Parmax Pharma Ltd
Parmax Pharma Ltd News Hub
Parmax Pharma reports standalone net profit of Rs 0.01 crore in the June 2024 quarter
Net profit of Parmax Pharma reported to Rs 0.01 crore in the quarter ended June 2024 as against net
Read more
16 Aug 24
Parmax Pharma to declare Quarterly Result
Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 August 2024. Powere
Read more
09 Aug 24
Parmax Pharma to conduct AGM
Parmax Pharma announced that the Annual General Meeting (AGM) of the company will be held on 30 Sept
Read more
18 Sept 24
Parmax Pharma to discuss results
Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 November 2024 Power
Read more
07 Nov 24
Document
Annual Reports
N/A
Credit Ratings
N/A
Concalls
Data not available
Data not available
Popular Search
About Parmax Pharma Ltd
- Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
- The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.
- The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
- The Company then discontinued their business activities for few years due to various reasons.
- Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.
FAQs for Quarterly Results of Parmax Pharma Ltd
What key financial metrics are included in Parmax Pharma Ltd's quarterly results?
When does Parmax Pharma Ltd announce its quarterly results?
How does Parmax Pharma Ltd's quarterly performance impact its stock price?
What is the impact of Parmax Pharma Ltd's quarterly results on dividends?
Are there any special announcements usually made during Parmax Pharma Ltd's quarterly results?
